论文部分内容阅读
目的评价神经节苷脂对脑瘫患儿的疗效及安全性,为其临床应用提供参考。方法检索Pubmed、Embase、Cochrane图书馆、中国生物医学文献数据库、中国期刊全文数据库及万方数字化全文期刊数据库,检索时间为建库至2015年10月。纳入有关神经节苷脂治疗脑瘫患儿的随机对照试验,对显效、有效率进行有序分类变量的Meta分析;对总有效率进行二分类变量的Meta分析;对患儿发育商评分(developmental quotient,DQ)进行连续变量的Meta分析。结果共纳入10个随机对照试验,共计806例患儿,对显效、有效率分析,其相对危险度(odds ratio,OR)为2.63,95%CI:1.95~3.53;对总有效率进行分析,其OR值为4.74,95%CI:2.99~7.52;神经节苷脂使DQ评分提高,SMD=1.30,95%CI:0.33~2.27。结论神经节苷脂对脑瘫患儿治疗效果良好,可改善患儿的症状。
Objective To evaluate the efficacy and safety of gangliosides in children with cerebral palsy and provide reference for its clinical application. Methods Pubmed, Embase, Cochrane Library, China Biomedical Literature Database, Chinese Journal Full-text Database and Wanfang Digitized Full-text Journal Database were searched. The search time was from the database to October 2015. A randomized controlled trial of gangliosides in the treatment of children with cerebral palsy was included in the Meta-analysis of categorical variables with markedly effective and efficient; Meta-analysis of the dichotomous variables of the total effective rate; and the developmental quotient , DQ) for meta-analysis of continuous variables. Results A total of 10 randomized controlled trials were included in this study. A total of 806 children were included in this study. The odds ratio (OR) was 2.63 and 95% CI of 1.95 ~ 3.53 for effective and effective analysis. The total effective rate The OR was 4.74, 95% CI: 2.99 ~ 7.52; gangliosides increased DQ score, SMD = 1.30, 95% CI: 0.33 ~ 2.27. Conclusion Ganglioside treatment of children with cerebral palsy good effect, can improve children’s symptoms.